JP7144050B2 - ５’－ホスホロチオラート ｍＲＮＡ ５’－末端（キャップ）類似体、それを含むｍＲＮＡ、それらを得る方法およびそれらの使用方法 - Google Patents

５’－ホスホロチオラート ｍＲＮＡ ５’－末端（キャップ）類似体、それを含むｍＲＮＡ、それらを得る方法およびそれらの使用方法 Download PDF

Info

Publication number
JP7144050B2
JP7144050B2 JP2018537845A JP2018537845A JP7144050B2 JP 7144050 B2 JP7144050 B2 JP 7144050B2 JP 2018537845 A JP2018537845 A JP 2018537845A JP 2018537845 A JP2018537845 A JP 2018537845A JP 7144050 B2 JP7144050 B2 JP 7144050B2
Authority
JP
Japan
Prior art keywords
mrna
cap
phosphorothiolate
independently selected
gspp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018537845A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504837A5 (enExample
JP2019504837A (ja
Inventor
ジェミエリティ，ヤセク
ファク－ドンブロスカ，カジャ
ボイチャック，ブラジェイ
バラノフスキー，マレク
ノヴィツカ，アンナ
コヴァルスカ，ヨアンナ
シコルスキ，パヴェル
ヴァルミンスキ，マルチン
Original Assignee
ユニヴェルシテット ワルシャウスキ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴェルシテット ワルシャウスキ filed Critical ユニヴェルシテット ワルシャウスキ
Publication of JP2019504837A publication Critical patent/JP2019504837A/ja
Publication of JP2019504837A5 publication Critical patent/JP2019504837A5/ja
Application granted granted Critical
Publication of JP7144050B2 publication Critical patent/JP7144050B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/02—Phosphorylation
    • C07H1/04—Introducing polyphosphoric acid radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2018537845A 2016-01-29 2017-01-27 ５’－ホスホロチオラート ｍＲＮＡ ５’－末端（キャップ）類似体、それを含むｍＲＮＡ、それらを得る方法およびそれらの使用方法 Active JP7144050B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PLPL415967 2016-01-29
PL415967A PL415967A1 (pl) 2016-01-29 2016-01-29 5'-tiofosforanowe analogi końca 5' mRNA (kapu), sposób ich otrzymywania i zastosowanie
PCT/IB2017/050447 WO2017130151A1 (en) 2016-01-29 2017-01-27 5'-phosphorothiolate mrna 5'-end (cap) analogs, mrna comprising the same, method of obtaining and uses thereof

Publications (3)

Publication Number Publication Date
JP2019504837A JP2019504837A (ja) 2019-02-21
JP2019504837A5 JP2019504837A5 (enExample) 2020-01-23
JP7144050B2 true JP7144050B2 (ja) 2022-09-29

Family

ID=58387852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018537845A Active JP7144050B2 (ja) 2016-01-29 2017-01-27 ５’－ホスホロチオラート ｍＲＮＡ ５’－末端（キャップ）類似体、それを含むｍＲＮＡ、それらを得る方法およびそれらの使用方法

Country Status (11)

Country Link
US (1) US11066436B2 (enExample)
EP (1) EP3408276B1 (enExample)
JP (1) JP7144050B2 (enExample)
KR (1) KR102742219B1 (enExample)
CN (1) CN109071589A (enExample)
AU (1) AU2017211693B2 (enExample)
CA (1) CA3011663C (enExample)
EA (1) EA038834B1 (enExample)
ES (1) ES2879802T3 (enExample)
PL (2) PL415967A1 (enExample)
WO (1) WO2017130151A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE112020002327T5 (de) * 2019-05-10 2022-07-14 New England Biolabs, Inc. Chemisches verkappen für matrizenwechsel
CN110907358B (zh) * 2019-12-09 2022-08-30 福建师范大学 一种光微流微泡腔铅离子传感器的实现装置及方法
PL432884A1 (pl) * 2020-02-12 2021-08-16 Uniwersytet Warszawski Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
CN113278665A (zh) * 2020-08-20 2021-08-20 深圳市瑞吉生物科技有限公司 一种Cap2结构5′帽子类似物及其制备方法和应用
WO2022051677A1 (en) 2020-09-04 2022-03-10 Verve Therapeutics, Inc. Compositions and methods for capping rnas
CN119137271A (zh) * 2022-03-01 2024-12-13 维乎医疗有限公司 用于加帽rna的组合物和方法
CN114685588B (zh) * 2022-05-05 2024-03-29 江苏申基生物科技有限公司 一种含开环核苷结构的起始加帽寡核苷酸引物
CN116143855B (zh) * 2022-11-08 2023-11-28 江苏申基生物科技有限公司 一种乙烯基膦酸修饰的mRNA帽类似物及其制备方法和应用
EP4464713A1 (en) 2023-05-18 2024-11-20 Siec Badawcza Lukasiewicz - PORT Polski Osrodek Rozwoju Technologii Circular rna analogs, preparation and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008546424A (ja) 2005-06-28 2008-12-25 アジェンコート パーソナル ジェノミクス コーポレイション 修飾ポリヌクレオチドを作製する方法および配列決定する方法
JP2011522542A (ja) 2008-06-06 2011-08-04 ウニヴェルシテ ワルシャワスキ ｍＲＮＡＣＡＰ類似体
JP2013501014A (ja) 2009-08-05 2013-01-10 バイオエヌテック アーゲー ５’末端キャップ修飾されたｒｎａを含有するワクチン組成物
WO2015021432A1 (en) 2013-08-08 2015-02-12 The Scripps Research Institute A method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2167523T1 (sl) * 2007-06-19 2014-09-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Sinteza in uporaba anti-reverznih fosforotioatnih analogov kape obveščevalne RNA
JP6567494B2 (ja) * 2013-03-14 2019-08-28 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ４’−チオ−修飾ヌクレオチドを有するリボ核酸及び関連方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008546424A (ja) 2005-06-28 2008-12-25 アジェンコート パーソナル ジェノミクス コーポレイション 修飾ポリヌクレオチドを作製する方法および配列決定する方法
JP2011522542A (ja) 2008-06-06 2011-08-04 ウニヴェルシテ ワルシャワスキ ｍＲＮＡＣＡＰ類似体
JP2013501014A (ja) 2009-08-05 2013-01-10 バイオエヌテック アーゲー ５’末端キャップ修飾されたｒｎａを含有するワクチン組成物
WO2015021432A1 (en) 2013-08-08 2015-02-12 The Scripps Research Institute A method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Tetrahedron Letters，1997年，Vol.38, No.6，pp.1021-1024

Also Published As

Publication number Publication date
KR102742219B1 (ko) 2024-12-13
EP3408276A1 (en) 2018-12-05
CN109071589A (zh) 2018-12-21
CA3011663C (en) 2023-10-31
WO2017130151A1 (en) 2017-08-03
ES2879802T3 (es) 2021-11-23
CA3011663A1 (en) 2017-08-03
AU2017211693B2 (en) 2021-09-09
JP2019504837A (ja) 2019-02-21
US20190300563A1 (en) 2019-10-03
AU2017211693A1 (en) 2018-08-09
KR20180100595A (ko) 2018-09-11
EP3408276B1 (en) 2021-04-07
PL3408276T3 (pl) 2021-10-25
EA201891429A1 (ru) 2019-02-28
PL415967A1 (pl) 2017-07-31
US11066436B2 (en) 2021-07-20
EA038834B1 (ru) 2021-10-26

Similar Documents

Publication Publication Date Title
JP7144050B2 (ja) ５’－ホスホロチオラート ｍＲＮＡ ５’－末端（キャップ）類似体、それを含むｍＲＮＡ、それらを得る方法およびそれらの使用方法
CN113603739B (zh) 一种加帽类似物及其应用
AU2009256131B2 (en) mRNA cap analogs
CA3167563A1 (en) Novel mrna 5'-end cap analogs modified within phosphate residues, rna molecule incorporating the same, uses thereof and method of synthesizing rna molecule or peptide
EP3067359A1 (en) Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
Rydzik et al. mRNA cap analogues substituted in the tetraphosphate chain with CX2: identification of O-to-CCl2 as the first bridging modification that confers resistance to decapping without impairing translation
PL248416B1 (pl) Nowe analogi kapu końca 5’ mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
AU2008265683A1 (en) Synthesis and use of anti-reverse phosphorothioate analogs of the messenger RNA cap
EP2961757A1 (en) Cell-penetrating oligonucleotides
HK1260250A1 (en) 5′-phosphorothiolate mrna 5′-end (cap) analogs, mrna comprising the same, method of obtaining and uses thereof
HK1257846A1 (en) Process for preparing phosphate compound bearing isotope
WO2023111597A1 (en) Therapeutic oligonucleotides having an inter-nucleoside amide linkage
HK1242326A (en) Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap
HK1242326A1 (en) Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap
HK1195315A (en) Process for preparing phosphate compound bearing isotope
PL214850B1 (pl) Cząsteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub białka

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210429

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211203

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20220112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220601

RD14 Notification of resignation of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7434

Effective date: 20220629

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220815

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220908

R150 Certificate of patent or registration of utility model

Ref document number: 7144050

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250